Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 4:12 pm Unchanged | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 3,196,876 5.9% | 0 (Unchanged) | View |
| 2023-02-14 4:06 pm Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | BRAIDWELL LP | 3,469,674 6.45% | 3,469,674 (New Position) | View |
| 2023-02-14 11:58 am Sale | 13G | Crinetics Pharmaceuticals, Inc. CRNX | BIOTECHNOLOGY VALUE FUND L P | 2,736,613 5.1% | -267,266 (-8.90%) | View |
| 2023-02-09 09:59 am Sale | 13G | Crinetics Pharmaceuticals, Inc. CRNX | FMR LLC | 1,883,118 3.499% | -1,839,176 (-49.41%) | View |
| 2023-02-08 11:32 am Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | DRIEHAUS CAPITAL MANAGEMENT LLC | 5,624,744 10.45% | 831,106 (+17.34%) | View |
| 2023-02-06 2:51 pm Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | WELLINGTON MANAGEMENT GROUP LLP | 2,804,485 5.21% | 2,804,485 (New Position) | View |
| 2023-01-31 1:58 pm Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | BlackRock Inc. BLK | 3,917,489 7.3% | 641,319 (+19.58%) | View |
| 2022-04-25 7:02 pm Unchanged | 13D | Crinetics Pharmaceuticals, Inc. CRNX | PERCEPTIVE ADVISORS LLC | 5,333,532 10% | 0 (Unchanged) | View |
| 2022-04-20 9:17 pm Purchase | 13D | Crinetics Pharmaceuticals, Inc. CRNX | PERCEPTIVE ADVISORS LLC | 5,333,532 10% | 1,674,151 (+45.75%) | View |
| 2022-02-14 09:08 am Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | Deep Track Capital LP | 1,900,000 4% | 1,334 (+0.07%) | View |
| 2022-02-11 5:22 pm Sale | 13G | Crinetics Pharmaceuticals, Inc. CRNX | Vivo Capital VIII LLC | 0 0% | -1,819,600 (Position Closed) | View |
| 2022-02-11 4:19 pm Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | ORBIMED ADVISORS LLC | 3,196,876 6.7% | 443,309 (+16.10%) | View |
| 2022-02-10 8:21 pm Sale | 13G | Crinetics Pharmaceuticals, Inc. CRNX | Versant Venture Capital V L.P. | 382,961 0.8% | -1,512,041 (-79.79%) | View |
| 2022-02-10 4:30 pm Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | Struthers Richard Scott | 1,978,334 4.2% | 274,339 (+16.10%) | View |
| 2022-02-03 4:41 pm Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | BlackRock Inc. BLK | 3,276,170 6.9% | 1,162,975 (+55.03%) | View |
| 2022-01-10 1:26 pm Sale | 13G | Crinetics Pharmaceuticals, Inc. CRNX | FMR LLC | 3,722,294 7.836% | -1,216,055 (-24.62%) | View |
| 2022-01-10 11:09 am Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | DRIEHAUS CAPITAL MANAGEMENT LLC | 4,793,638 10.09% | 4,793,638 (New Position) | View |
| 2021-10-29 4:29 pm Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | BIOTECHNOLOGY VALUE FUND L P | 3,003,879 6.5% | 3,003,879 (New Position) | View |
| 2021-04-22 5:56 pm Purchase | 13G | Crinetics Pharmaceuticals, Inc. CRNX | Deep Track Capital LP | 1,898,666 5.05% | 1,898,666 (New Position) | View |
| 2021-02-16 4:39 pm Sale | 13G | Crinetics Pharmaceuticals, Inc. CRNX | RA CAPITAL MANAGEMENT L.P. | 564,102 1.7% | -1,311,107 (-69.92%) | View |